On Thursday, September 23rd RESIST-TB hosted this webinar webinar featuring Dr. Keertan Dheda, who will present the results of the recently-completed NeXT clinical trial for MDR-TB. This study evaluated the impact of a new injection-free six-to-nine month treatment regimen of linezolid, bedaquiline, levofloxacin, pyrazinamide (PZA) and ethionamide/high dose isoniazid (INH) compared to the conventional empiric injection-based regimen. Read more here.
top of page
Recent Posts
See AllThis report marks the midway point of the 1/4/6×24 Campaign, which calls for the universal implementation of the best available TB regimens — as little as one month or once weekly for TB prevention, f
20
Their annual review provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB). View the full
30
The Indonesia AIDS Coalition (IAC) and Indonesia for Global Justice (IGJ) have filed a patent opposition for the Tuberculosis (TB) drug Bedaquiline with dispersible tablet formulations (hereinafter, i
380
bottom of page